Name | Title | Contact Details |
---|
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.
Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on transforming patient lives through the development of innovative and ground-breaking prescription therapeutics.
Founded in 2007, we are a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.
Founded in 1993, Diamatrix helped usher in a new era of cataract surgery with its revolutionary Trapezoid diamond blade. Designed in conjunction with Clear Cornea pioneer, Dr. Charles H. Williamson, M.D. of the Williamson Eye Center in Baton Rouge, thi...